Payment of 2642 shares by John Varner of Genprex subject to Rule 16b-3
| GNPX Stock | USD 1.16 0.10 9.43% |
Slightly above 57% of all Genprex's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Genprex suggests that some traders are interested. Genprex's investing sentiment can be driven by a variety of factors including economic data, Genprex's earnings reports, geopolitical events, and overall market trends.
Genprex |
Filed transaction by Genprex Inc director. Payment of exercise price or tax liability by delivering or withholding securities
Read at macroaxis.com
Genprex Fundamental Analysis
We analyze Genprex's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genprex using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genprex based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Genprex is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Genprex Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genprex stock to make a market-neutral strategy. Peer analysis of Genprex could also be used in its relative valuation, which is a method of valuing Genprex by comparing valuation metrics with similar companies.
Peers
Genprex Related Equities
| XFOR | X4 Pharmaceuticals | 11.67 | ||||
| RNAZ | Transcode Therapeutics | 2.91 | ||||
| GLSI | Greenwich Lifesciences | 2.27 | ||||
| KOD | Kodiak Sciences | 1.19 | ||||
| MREO | Mereo BioPharma | 0.27 | ||||
| ELEV | Elevation Oncology | 4.48 | ||||
| HEPA | Hepion Pharmaceuticals | 4.84 | ||||
| RVPH | Reviva Pharmaceuticals | 5.78 | ||||
| CGTX | Cognition Therapeutics | 5.88 | ||||
| RVPHW | Reviva Pharmaceuticals | 11.43 |
Additional Tools for Genprex Stock Analysis
When running Genprex's price analysis, check to measure Genprex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genprex is operating at the current time. Most of Genprex's value examination focuses on studying past and present price action to predict the probability of Genprex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genprex's price. Additionally, you may evaluate how the addition of Genprex to your portfolios can decrease your overall portfolio volatility.